课题基金 / 基金详情

Metformin for Antipsychotic-induced Weight Gain in Adults with Intellectual Disability Study: a Double-Blind Randomized Control Trial

Metformin for Antipsychotic-induced Weight Gain in Adults with Intellectual Disability Study: a Double-Blind Randomized Control Trial
二甲双胍治疗智力障碍成人抗精神病药物引起的体重增加研究:双盲随机对照试验
批准号:
443707
负责人:
Agarwal Sri Mahavir
金额:
$55.45万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2021
资助国家:
加拿大
项目状态:
未结题
起止时间:
2021-04-01 至 2025-10-01

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
近50%的智力残疾成年人超重或肥胖。三分之一的ID患者服用抗精神病药物,这些药物会导致体重显著增加,导致肥胖和其他相关疾病
英文摘要
Close to 50% of adults with intellectual disability (ID) are overweight or obese. One third of patients with ID are prescribed antipsychotic medications, which are known to cause significant weight gain, leading to obesity and other related diseases like
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金